Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
9 min read
Guangdong Shuanglin Biological Pharmaceutical Co. Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Guangdong Shuanglin Biological Pharmaceutical Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial sign
Latest Hotspot
8 min read
Guangdong Saier Biotechnology Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Guangdong Saier Biotechnology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreac
Latest Hotspot
8 min read
GUANGDONG LEIYUNSHANG PHARMACEUTICAL CO., LTD. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for GUANGDONG LEIYUNSHANG PHARMACEUTICAL CO., LTD.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and
Latest Hotspot
9 min read
Grand Theravac Life Science Nanjing Co. Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Grand Theravac Life Science Nanjing Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and ou
Latest Hotspot
9 min read
Gluetacs Therapeutics (Shanghai) Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Gluetacs Therapeutics (Shanghai) Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outr
Latest Hotspot
9 min read
GlaxoSmithKline KK Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for GlaxoSmithKline KK: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
8 min read
Glaukos Corp. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Glaukos Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Genmab A/S Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Genmab A/S: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Generium ZAO Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Generium ZAO: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
GE Healthcare Technologies, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for GE Healthcare Technologies, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ratio
Latest Hotspot
9 min read
GC Biopharma Corp. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for GC Biopharma Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
8 min read
Galderma SA (Switzerland) Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Galderma SA (Switzerland): pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.